Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.62%
#2 Luxxcoin Luxxcoin +45.27%
#3 ResearchCoin ResearchCoin +22.78%
#4 Reactive Network Reactive Network +20.67%
#5 Orderly Network Orderly Network +16.77%
#6 Layer3 Layer3 +13.71%
#7 Bitgert Bitgert +13.08%
#8 Aria.AI Aria.AI +11.86%
#9 Useless Coin Useless Coin +9.66%
#10 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.53%
Coin of the day
Resolv wstUSR Resolv wstUSR
Innstillinger
Språk
NORSK
Valuta
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Rangering i aksjer #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Aksjekurs
$99.32
Markedsverdi
$48.20B
Endring (1 dag)
0.98%
Endring (1 år)
-32.14%
Land
AU
Handel CSL Limited (CSL)

Kategori

Healthcare
P/B-forhold for CSL Limited (CSL)
P/B-forhold per April 2026 TTM: 2.55
Ifølge CSL Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 2.55. Ved slutten av 2024 hadde selskapet et P/B-forhold på 5.43.
P/B-historikk for CSL Limited fra 2000 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) 2.55 -35.36%
2025 3.94 -27.38%
2024 5.43 44.67%
2023 3.75 -8.59%
2022 4.11 -64.62%
2021 11.60 -41.84%
2020 19.95 52.81%
2019 13.06 -17.71%
2018 15.87 -20.12%
2017 19.87 32.34%
2016 15.01 -0.22%
2015 15.04 47.75%
2014 10.18 1.25%
2013 10.06 70.32%
2012 5.91 28.39%
2011 4.60 -10.55%
2010 5.14 17.45%
2009 4.38 -40.16%
2008 7.31 -12.44%
2007 8.35 25.21%
2006 6.67 58.64%
2005 4.21 53.56%
2004 2.74 23.37%
2003 2.22 -67.73%
2002 6.88 -56.70%
2001 15.89 71.69%
2000 9.25 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.2875 107.61%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.074 138.50%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.5436 -0.13%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.5196 77.46%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.0209 136.41%
NL